A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis

This study will assess the efficacy and safety of tocilizumab compared with placebo in
participants with SSc across approximately 120 planned global study sites. The study will
consist of a 48-week, double-blind, placebo-controlled period followed by a 48-week
open-label treatment period. Participants will be assigned, in a 1:1 ratio, to double-blind
treatment with active tocilizumab or matching placebo. In the open-label period, eligible
participants from either arm may receive active tocilizumab.